The effect of baricitinib add‐on therapy in atopic dermatitis patients treated with dupilumab

Kook, Hyung Don; Hong, Narang; Lee, Dong Heon; Jung, Hye Jung; Park, Mi Youn; Ahn, Jong Woong

doi:10.1111/dth.15525

Cited by 3 publications

(2 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Kook et al 10 . reported the use of baricitinib in patients who have been using dupilumab in a real‐world setting.…”

Section: Discussionmentioning

confidence: 99%

Real‐world experience of baricitinib in atopic dermatitis: including add‐on therapy for patients using dupilumab

Lim,

Kwon,

Lew

2023

Int J Dermatology

View full text Add to dashboard Cite

BackgroundLittle real‐world experience regarding the use of baricitinib, an oral selective JAK1/JAK2 inhibitor, for treating moderate to severe atopic dermatitis (AD) has been reported.MethodsThis study aimed to assess the overall outcomes in Korean patients with AD treated with baricitinib. All patients with moderate to severe AD treated with baricitinib between June 2021 and June 2022 were included, and their cases were retrospectively analyzed using medical records. Patients with moderate to severe AD, aged ≥18 years who had failed previous therapies, including those who demonstrated unsatisfactory improvement with dupilumab, were prescribed baricitinib. Patients whose follow‐up period was <8 weeks were excluded. The dermatologist evaluated the AD status, including eczema area and severity index (EASI), itch Numeric Rating Scale, and improvement of remaining lesions despite dupilumab therapy.ResultsWe analyzed 34 AD patients who received baricitinib. Twelve patients treated with dupilumab were additionally prescribed baricitinib due to unsatisfactory treatment effects and demonstrated improvement in the remaining lesions despite dupilumab treatment. Their itching improved after 1.4 weeks. Among them, eight patients (66.7%) had head and neck dermatitis, and seven of them demonstrated improvement after the coadministration of baricitinib. Among the other 22 patients who were prescribed baricitinib only, 10 patients (45.5%) achieved EASI 75 at 8 weeks, with five (22.7%) revealing EASI 90.ConclusionsOverall, baricitinib was well tolerated and resulted in clinical improvement in AD patients in a real‐world clinical setting. Additionally, baricitinib may be beneficial in treating lesions refractory to dupilumab therapy.

show abstract

“…Kook et al 10 . reported the use of baricitinib in patients who have been using dupilumab in a real‐world setting.…”

Section: Discussionmentioning

confidence: 99%

Real‐world experience of baricitinib in atopic dermatitis: including add‐on therapy for patients using dupilumab

Lim,

Kwon,

Lew

2023

Int J Dermatology

View full text Add to dashboard Cite

show abstract

“…In our recent report into AD patients with insufficient response to dupilumab, indeed, baricitinib was revealed as an effective add-on therapy for acute aggravation or further improvement. 9 In addition to add-on therapy, baricitinib treatment alone can be effective for dupilumab-refractory AD patients, which can also prevent unnecessary adverse events of dupilumab.…”

mentioning

confidence: 99%

Successful treatment of atopic dermatitis refractory to dupilumab with baricitinib

Lee

Park

Hong

et al. 2022

Dermatologic Therapy

Self Cite

View full text Add to dashboard Cite

Atopic dermatitis (AD) is the most common chronic inflammatory skin disorder worldwide. Its pathogenesis encompasses various immune responses and associated inflammations. Not only type 2 inflammatory pathway, which is the dominant pathway of AD, but also types 1 and 3 inflammatory pathways are also revealed to be involved in the disease pathogenesis. 1,2 Due to its complex pathophysiology, it was challenging to manage only with available treatments. 3 With advances in the understanding of disease mechanisms, however, novel potential therapeutic options have been emerging in recent years. The first

show abstract

Combining an anti‐IL‐4Rα biologic with a JAK1 inhibitor leads to a higher treatment response in resistant atopic dermatitis versus monotherapy alone: A case series

Ferreirinha,

Simões Farinha,

Pessoa e Costa

et al. 2024

Acad Dermatol Venereol

View full text Add to dashboard Cite

The effect of baricitinib add‐on therapy in atopic dermatitis patients treated with dupilumab

Cited by 3 publications

References 9 publications

Real‐world experience of baricitinib in atopic dermatitis: including add‐on therapy for patients using dupilumab

Real‐world experience of baricitinib in atopic dermatitis: including add‐on therapy for patients using dupilumab

Successful treatment of atopic dermatitis refractory to dupilumab with baricitinib

Combining an anti‐IL‐4Rα biologic with a JAK1 inhibitor leads to a higher treatment response in resistant atopic dermatitis versus monotherapy alone: A case series

Contact Info

Product

Resources

About